Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that a new formal submission has been made by the Company in Europe for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH). The trademarked name for the product in the application is NYMOZARFEX (TM). The Marketing Authorization Application (MAA) was submitted to the Danish authorities. The Company will provide further information, including other expected submissions, when the information becomes available.
https://finance.yahoo.com/news/nymox-announces-marketing-submission-nymozarfex-143000386.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.